ClinicalTrials.gg
RecruitingNCT06166030IRPCUpdated Dec 12, 2023

IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS.

A Phase 3 interventional study of Nutritional blend (ImmuneRecov). in Long Covid19, Dietary Supplements and Respiratory Tract Infections, sponsored by Federal University of São Paulo. Recruiting at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-12.

Sponsored by Federal University of São Paulo · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil — 9 open to participants now, 10 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Brazil.

Planned enrollment
9th of 18
58 · median 57
Started
2023
with 5 others
Phase 3
3 of 21
2 open now
Registered
13th of 21
by date
Lead sponsor
1 of 21
Federal University of São Paulo

Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 3, and was the 13th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

9 of the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, or all of them as a file.
02

Study summary

Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients. Objectives: Thus, the present study investigated whether 30 days of supplementation with a nutritional blend (ImmuneRecov®; composition: whey protein concentrate, astaxanthin, creatine, selenium, vitamin C, glutamic acid, tryptophan, magnesium) would help to minimize the respiratory (lung function) and muscular (respiratory and peripheral muscles) sequelae in post-COVID-19 patients.

Read the detailed description

Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients. Objectives: Thus, the present study investigated whether 30 days of supplementation with a nutritional blend (ImmuneRecov®; composition: whey protein concentrate, astaxanthin, creatine, selenium, vitamin C, glutamic acid, tryptophan, magnesium) would help to minimize the respiratory (lung function) and muscular (respiratory and peripheral muscles) sequelae in post-COVID-19 patients. Design: This is a non-controlled open label prospective clinical study. Methods: Fifty-eight post-COVID-19 patients were recruited and twenty-four accepted to take the nutritional blend, while twenty-four did not accept but required to participate in the evaluations and 10 refused to participate. So, the patients were evaluated before the 14th day after hospital discharge and after 30 days of use of the nutritional blend or control (no supplementation).

03

Conditions studied

  • Long Covid19
  • Dietary Supplements
  • Respiratory Tract Infections
  • Inflammation

Keywords

  • COVID-19
  • dietary supplementation
  • inflammation
  • lung function
  • muscle strength
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: The inclusion criteria encompassed post-COVID-19 patients with a confirmed COVID-19 diagnosis through a positive RT-PCR test, who also required hospitalization, meeting the criteria for moderate severity classification as defined by the World Health Organization (WHO). In summary, according to the WHO, moderate illness is characterized by individuals who exhibit signs of lower respiratory disease during clinical assessment or imaging and maintain an oxygen saturation level (SpO2) of ≥94% while breathing room air at sea level.

Exclusion Criteria: Exclusion criteria included individuals discharged from the hospital for more than 14 days and those who initiated physical activity or began taking any dietary supplements or vitamins.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Effects of ImmuneRecov on Lung Function and Immune Response

    Effects of 30 days supplementation with ImmuneRecov on Lung Function and Immune Response of post-COVID-19 patients.

    Dietary Supplement: Nutritional blend (ImmuneRecov).

  • Experimental
    Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength

    Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength

    Dietary Supplement: Nutritional blend (ImmuneRecov).

Interventions

  • Dietary supplementNutritional blend (ImmuneRecov).

    Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.

06

What researchers measure

Primary outcomes

  1. Effects of ImmuneRecov on Lung Function and Immune Response

    Effects of ImmuneRecov on Lung Function and Immune Response

    Time frame: Effects of 30 days supplementation with ImmuneRecov on Lung Function and Immune Response

Secondary outcomes

  1. Effects of ImmuneRecov on Peripheral and Respiratory Muscle Strength

    Effects of 30 days of ImmuneRecov supplementation on Peripheral and Respiratory Muscle Strength

    Time frame: Effects of 30 days of ImmuneRecov supplementation on Peripheral and Respiratory Muscle Strength

07

Study locations

2 of 2 sites recruiting
  • Laboratory of Pulmonary and Exercise Immunology
    Sao Jose dos Campos, Sao Paulo 12231280, Brazil
    Recruiting
    • Rodolfo de Paula Vieira, MSc., PhD. · Contactrpvieira@unifesp.br · 55 12 991410615
    • Rodolfo de Paula Vieira, MSc., PhD · Contactrpvieira@unifesp.br · 55 12 991410615
    • Rodolfo de Paula Vieira, MSc., PhD · Principal investigator
  • Laboratory of Pulmonary and Exercise Immunology - Federal University of Sao Paulo
    São José dos Campos, SP 12231-280, Brazil
    Recruiting
    • Rodolfo de Paula Vieira, MSc., PhD. · Contactrpvieira@unifesp.br · +55 12 99141-0615
    • Rodolfo de Paula Vieira, MSc., PhD · Contactrpvieira@unifesp.br · +55 12 99141-0615
    • Rodolfo de Paula Vieira, PhD · Principal investigator
08

References and documents

Publications

  • Prokopidis K, Mazidi M, Sankaranarayanan R, Tajik B, McArdle A, Isanejad M. Effects of whey and soy protein supplementation on inflammatory cytokines in older adults: a systematic review and meta-analysis. Br J Nutr. 2023 Mar 14;129(5):759-770. doi: 10.1017/S0007114522001787. Epub 2022 Jun 16. PubMed 35706399 ↗
  • Franco JVA, Garegnani LI, Oltra GV, Metzendorf MI, Trivisonno LF, Sgarbossa N, Ducks D, Heldt K, Mumm R, Barnes B, Scheidt-Nave C. Long-Term Health Symptoms and Sequelae Following SARS-CoV-2 Infection: An Evidence Map. Int J Environ Res Public Health. 2022 Aug 11;19(16):9915. doi: 10.3390/ijerph19169915. PubMed 36011562 ↗
  • Wang S, Qi X. The Putative Role of Astaxanthin in Neuroinflammation Modulation: Mechanisms and Therapeutic Potential. Front Pharmacol. 2022 Jun 24;13:916653. doi: 10.3389/fphar.2022.916653. eCollection 2022. PubMed 35814201 ↗

Individual participant data

Plan to share: Yes — All data collected and all measurements done will be shared and properly explained to all participants in a private and previously scheduled meeting

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Beginning: 11 December 2023. End: 31 January 2024.

Access criteria: The principal investigator will have access to IPS and all data through data bank used in the Laboratory of Pulmonary and Exercise Immunology.

Data sharing details ↗ · www.plataformabrasil.saude.gov.br

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2023
First posted
Dec 12, 2023
StartActual
Dec 10, 2023
Primary completionEst.
Dec 10, 2024
CompletionEst.
Dec 15, 2024
Last update
Dec 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06166030
Responsible party
Rodolfo de Paula Vieira (Professor, Federal University of São Paulo) — Principal investigator
First posted
Dec 12, 2023
Start date
Dec 10, 2023
Primary completion
Dec 10, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Dec 12, 2023

Study contacts

Rodolfo de Paula Vieira, BSc., MSc., PhD.
Contact
rodrelena@yahoo.com.br
55 12 991410615
Rodolfo de Paula Vieira, BSc., MSc., PhD.
principal investigator · Federal University of São Paulo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion